RESUMO
A multicentric, open, prospective, observational and no-randomized clinical trial was carried out in Spain with 190 postmenopausal women receiving a soy preparation rich in isoflavones (PHYTO SOYA, capsules containing 17.5 mg isoflavones). The main object of the present study was to investigate its efficacy in alleviating the symptomatology derived from the lack of estrogen, mainly hot flushes, but also other symptoms such as sleep disorder, anxiety, depression, vaginal dryness, loss of libido and bone pain. Each patient received 35 mg isoflavones per day in two doses. During the four months' treatment, a statistically significant decrease in the number of hot flushes with PHYTO SOYA was experienced by 80.82% women; only 5,48% patients did not improve with the treatment. The average reduction was 47.8%, which is equivalent to 4 hot flushes. All the other studied parameters also showed a statistically significant decrease. No severe side-effects were reported and tolerance was excellent. Treatment with PHYTO SOYA resulted in a significant improvement of the symptomatology that accompanies the lack of estrogen during menopause.
Assuntos
Climatério/efeitos dos fármacos , Estrogênios não Esteroides/uso terapêutico , Glycine max , Fogachos/tratamento farmacológico , Fitoterapia , Ansiedade/tratamento farmacológico , Pressão Sanguínea/efeitos dos fármacos , Cromatografia Líquida de Alta Pressão , Depressão/tratamento farmacológico , Estrogênios não Esteroides/efeitos adversos , Estrogênios não Esteroides/farmacologia , Feminino , Humanos , Isoflavonas/química , Isoflavonas/uso terapêutico , Menopausa/efeitos dos fármacos , Metrorragia/induzido quimicamente , Pessoa de Meia-Idade , Estrutura Molecular , Dor/induzido quimicamente , Fitoestrógenos , Extratos Vegetais/efeitos adversos , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Preparações de Plantas , Estudos Prospectivos , Transtornos do Sono-Vigília/tratamento farmacológico , Análise Espectral , Estatística como Assunto , Inquéritos e Questionários , Resultado do TratamentoRESUMO
No disponible
Assuntos
Gravidez , Feminino , Humanos , Fluorometria/métodos , Gonadotropina Coriônica Humana Subunidade beta/análise , Radioimunoensaio/métodos , Proteína Plasmática A Associada à Gravidez/análise , Biomarcadores , Fatores de Risco , AneuploidiaRESUMO
No disponible
Assuntos
Adulto , Gravidez , Feminino , Humanos , Diagnóstico Diferencial , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/tratamento farmacológico , Corticosteroides/uso terapêutico , Hidroxizina/administração & dosagem , Hidroxizina/uso terapêutico , Difenidramina/administração & dosagem , Difenidramina/uso terapêutico , Exantema/complicações , Desenvolvimento Fetal , Mortalidade Materna , Penfigoide Gestacional/diagnóstico , Penfigoide Bolhoso/fisiopatologia , Corticosteroides/farmacologia , Amenorreia/complicações , Amenorreia/diagnóstico , Diagnóstico Diferencial , Ciclosporina/administração & dosagem , Ciclosporina/uso terapêuticoRESUMO
To determine the need for contraception during Hormonal Replacement Therapy (HRT) in perimenopausal women, ultrasound monitoring of ovarian function was performed on 10 perimenopausal women in the second month of treatment. All patients were not at risk of unwanted pregnancy during the study period and had last regular menses at least three months before starting HRT. All of them received transdermal implants of 50 mg of estrogen, twice per week, and 10 mg of oral dydrogesterone on the fourth week. Ultrasound performed at treatment days 7, 14 and 21 of the second month revealed follicular development and rupture in 5 out of the 10 patients. Contraceptive implications are discussed.